CIK 0000310158
- Large accelerated filer
Merck & Co., Inc.
Sign in to watch- Ticker
- MRK
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NJ
- Entity type
- Operating
- EIN
- 221918501
- Phone
- +1 908-740-4000
- Business address
- 126 EAST LINCOLN AVENUE, P.O. BOX 2000, RAHWAY, NJ, 07065
- Former names
- Merck & Co. Inc., SCHERING PLOUGH CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $8,611,875
- in 1 filing
Net −$8,611,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-04 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth | Option exercise · Stock Option (Right to Buy) | −29,782 | 59,564 | ||
| 2021-11-04 | Litchfield Caroline EVP & CFO | Option exercise | +22,683 | 42,448.77 | ||
| 2021-11-04 | Litchfield Caroline EVP & CFO | Sale | −18,335 | $91.00 | $1.7M | 24,113.77 |
| 2021-11-04 | Litchfield Caroline EVP & CFO | Option exercise · Stock Option (Right to Buy) | −22,683 | 0 | ||
| 2021-11-03 | Karachun Rita A Sr. VP Fince-Global Controller | Option exercise | +25,000 | 60,798.97 | ||
| 2021-11-03 | Karachun Rita A Sr. VP Fince-Global Controller | Sale | −25,000 | $88.45 | $2.2M | 35,798.97 |
| 2021-11-03 | Karachun Rita A Sr. VP Fince-Global Controller | Option exercise · Stock Option (Right to Buy) | −25,000 | 16,997 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise | +35,287 | 74,449.14 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise | +30,175 | 104,624.14 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise | +19,394 | 124,018.14 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise | +11,414 | 135,432.14 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Sale | −96,270 | $87.91 | $8.5M | 39,162.14 |
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise · Stock Option (Right to Buy) | −35,287 | 0 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise · Stock Option (Right to Buy) | −30,175 | 0 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise · Stock Option (Right to Buy) | −19,394 | 9,698 | ||
| 2021-11-01 | Gerberding Julie L. EVP, Chief Patient Officer | Option exercise · Stock Option (Right to Buy) | −11,414 | 22,831 | ||
| 2021-11-01 | Clyburn Frank EVP & Pres ? Human Health | Option exercise | +19,915 | 117,010.09 | ||
| 2021-11-01 | Clyburn Frank EVP & Pres ? Human Health | Option exercise | +19,847 | 136,857.09 | ||
| 2021-11-01 | Clyburn Frank EVP & Pres ? Human Health | Sale | −39,762 | $87.87 | $3.5M | 97,095.09 |
| 2021-11-01 | Clyburn Frank EVP & Pres ? Human Health | Option exercise · Stock Option (Right to Buy) | −19,915 | 0 |
Page 40 of 42 · 823 trades